Bone Health Management in Men Commencing Androgen Deprivation Therapy for Prostate Cancer and Women Commencing Anti‐Oestrogen Therapy for Breast Cancer
Cancer Medicine · 2025-05 · 14 (9)
DOI: 10.1002/cam4.70873 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 13.05.2025. Verfasst von Ian Liang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Rheumatology and Orthopaedics, Royal Prince Alfred Hospital, Camperdown, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Breast Neoplasms, Prostatic Neoplasms, Androgen Antagonists, Osteoporosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Survival of patients with prostate and breast cancer, the commonest cancer in men and women, respectively, has markedly improved with advances in early diagnosis, treatment and multi‐disciplinary care by the oncology and surgical community. However, the use of increasingly potent endocrine therapies may cause bone loss, resulting in secondary osteoporosis. Review This review summarises the current management of cancer treatment‐induced bone loss in this group of patients at high risk of osteoporotic fractures with their attendant morbidity and mortality.
Conclusion
Bone health is an increasingly important part of cancer survivorship. Radiation and medical oncologists, urologists, bone health experts, general practitioners, healthcare professional bodies and bone health and cancer consumer organisations should increase awareness of the potential adverse effect of endocrine therapy on bone health. While this should never delay cancer treatment, bone health should be part of routine care for men and women receiving endocrine therapy for prostate and breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Rheumatology and Orthopaedics, Royal Prince Alfred Hospital, Camperdown, Sydney, New South Wales, Australia.
- Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia.
- Faculty of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.
- Department of Endocrinology, Westmead Hospital, Westmead, New South Wales, Australia.
- Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia.
- Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia.
ORCID-Profile: Ian Liang
Zitieren
APA
Liang, I., Brennan, S., Girgis, C., Hayden, A., Moujaber, T., Turner, S., Vasista, A., Grossmann, M., & Wong, P. K. K. (2025). Bone Health Management in Men Commencing Androgen Deprivation Therapy for Prostate Cancer and Women Commencing Anti‐Oestrogen Therapy for Breast Cancer. Cancer Medicine, 14(9). https://doi.org/10.1002/cam4.70873
Vancouver
Liang I, Brennan S, Girgis C, Hayden A, Moujaber T, Turner S, et al. Bone Health Management in Men Commencing Androgen Deprivation Therapy for Prostate Cancer and Women Commencing Anti‐Oestrogen Therapy for Breast Cancer. Cancer Medicine. 2025;14(9). doi:10.1002/cam4.70873
BibTeX
@article{Liang2025,
author = {Liang, Ian and Brennan, Sarah and Girgis, Christian and Hayden, Amy and Moujaber, Tania and Turner, Sandra and Vasista, Anuradha and Grossmann, Mathis and Wong, Peter K K},
title = {Bone Health Management in Men Commencing Androgen Deprivation Therapy for Prostate Cancer and Women Commencing Anti‐Oestrogen Therapy for Breast Cancer},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {9},
doi = {10.1002/cam4.70873}
}
EUVIMED